Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 23, 2023 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
September 06, 2023 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
August 29, 2023 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
August 14, 2023 17:36 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA...
July 20, 2023 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference

LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
July 18, 2023 07:03 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology

LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
June 29, 2023 17:04 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program

LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
June 16, 2023 07:38 ET | Source: Unicycive Therapeutics, Inc.

Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease,...
May 16, 2023 08:29 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update

Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress...
April 24, 2023 07:00 ET | Source: Unicycive Therapeutics, Inc.

Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress

LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...